Delivery Order SPE2DB22D2211-SPE2DB25FSDZA
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,709.46 for Dupixent 300 mg/2 ml pen injections on August 19, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with DLA. The place of performance is listed as Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order falls under AmerisourceBergen's comprehensive...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $25,169.28 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract employs firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,447.52 for Dupixent 300 mg/2 ml pen (2 ml) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $54,417.70 on August 14, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract action, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $11,417.87 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen (2 ml) on August 29, 2025, with an ultimate completion date of September 2, 2025. This is a firm fixed price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $13,253.95 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child action under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDZADelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $97,446.44 on August 29, 2025, for the supply of Dupixent 300 mg/2 ml pen (2 ml units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 2, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract under a larger vehicle, this delivery order falls under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which carries a maximum value of $999,999,999.00 and runs through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, moderate-to-severe asthma, and chronic rhinosinusitis with nasal polyps, making it a critical pharmaceutical asset for defense health operations. The company's federal contract portfolio demonstrates consistent capability in fulfilling competitively awarded medical supply requirements across diverse therapeutic domains, supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through flexible contract vehicles designed to ensure reliable pharmaceutical availability for military personnel and beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $97.4k | 8/29/25 |